---
title: "Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293807384.md"
description: "Guggenheim analyst Yatin Suneja reiterated a Buy rating on Spyre Therapeutics (SYRE) with an $115 price target. This follows Mizuho Securities' July 13 report, which also maintained a Buy rating and set a $120 price target for the healthcare stock."
datetime: "2026-07-25T01:25:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293807384.md)
  - [en](https://longbridge.com/en/news/293807384.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293807384.md)
generator: "portal-rs"
---

# Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim

In a report released yesterday, Yatin Suneja from Guggenheim reiterated a Buy rating on Spyre Therapeutics, with a price target of $115.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Suneja covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Abivax SA Sponsored ADR, and DBV Technologies SA – American. According to TipRanks, Suneja has an average return of 33.1% and a 57.75% success rate on recommended stocks. 

In a report released on July 13, Mizuho Securities also maintained a Buy rating on the stock with a $120.00 price target.

### Related Stocks

- [SYRE.US](https://longbridge.com/en/quote/SYRE.US.md)
- [PRAX.US](https://longbridge.com/en/quote/PRAX.US.md)
- [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md)
- [DBVT.US](https://longbridge.com/en/quote/DBVT.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)

## Related News & Research

- [LifeSci Capital Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/296003421.md)
- [Wedbush Keeps Their Buy Rating on Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/295548633.md)
- [Denison Mines (DNN) Receives a Buy from Roth MKM](https://longbridge.com/en/news/296056406.md)
- [Barclays Sticks to Its Buy Rating for Prosus (PROSF)](https://longbridge.com/en/news/296063490.md)
- [Barclays Keeps Their Buy Rating on RWE AG (0HA0)](https://longbridge.com/en/news/295941081.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**